In the intricate landscape of medical research, few areas offer as much promise and excitement as the study of the microbiome. Dr Michelle Fitzmaurice, a postdoctoral researcher at the UNSW Microbiome Research Centre, stands at the forefront of this burgeoning field, focusing her efforts on unravelling the complex relationship between our gut health and neurodegenerative diseases like dementia.
The microbiome and neurodegenerative diseases
“The role of the microbiome in various diseases, including neurodegenerative conditions, is incredibly significant,” Dr Fitzmaurice explains. Recent studies have highlighted a strong link between gut health and brain health, an area often referred to as the gut-brain axis. This research explores how microorganisms in our gut can influence the progression of diseases such as Alzheimer’s and Parkinson’s.
“A lot of the current research compares the microbiomes of healthy individuals with those of patients suffering from these diseases,” she says. “We see a reduction in microbial diversity and an increase in microorganisms associated with inflammation in those with neurodegenerative conditions.” One study stands out.
By transferring microbiome samples, “poo” from patients with Alzheimer’s or Parkinson’s into animal models, they observed a worsening of symptoms in these animals. “This suggests that disease-causing microorganisms play a crucial role, potentially by increasing harmful metabolites and decreasing beneficial ones.
Challenges and breakthroughs
Dr Fitzmaurice’s path into dementia research wasn’t straightforward. Initially working in a different field, she transitioned to the Microbiome Research Centre, where she became deeply involved in the Healthy Optimal Australian Microbiome Study. This study aims to map the microbiome of healthy individuals as a baseline for understanding changes seen in those with dementia.
Recruiting participants, especially those with dementia, has proven challenging. “Many carers of dementia patients have full-time responsibilities and find it difficult to participate in studies,” she explains. Despite these challenges, the importance of this work remains clear. One participant poignantly shared his motivation: “My wife died in my arms from dementia. Please do something.”
The future of dementia research
The potential to harness the microbiome for therapeutic purposes offers a promising new avenue for dementia treatment and prevention. With advanced technologies like next-generation sequencing, researchers can now analyse the DNA of microorganisms more efficiently, leading to new insights and potential treatments.
“The microbiome provides a new pathway to explore therapeutic products for dementia,” Dr Fitzmaurice notes. “If we can pinpoint the microbial causes of dementia and other neurodegenerative conditions, we have a pathway to change our approach to diagnosing and treating these diseases, potentially even from an early age.”
A call to action
Dr Fitzmaurice’s story underscores the vital importance of continued support for medical research. “We need your help to make our work more meaningful,” she urges. By contributing to the St George & Sutherland Medical Research Foundation (SSMRF), you can help unlock hope for those living with dementia.
As we approach the end of the financial year, consider making a tax-deductible donation to SSMRF’s medical research grants. Your support can drive significant advancements in dementia research, providing hope and potentially life-changing breakthroughs for countless individuals and their families.
Make a difference this EOFY. Donate to SSMRF and support groundbreaking dementia research. Together, we can make a significant impact.
To learn more about Dr Michelle Fitzmaurice and her work, watch our interview with her.
